7/26
08:21 am
ntra
New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma [Yahoo! Finance]
Low
Report
New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma [Yahoo! Finance]
7/26
08:00 am
ntra
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
Low
Report
New MultiCenter Prospective Study Demonstrates Signatera’s Clinical Utility in Merkel Cell Carcinoma
7/22
10:43 am
ntra
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises [Yahoo! Finance]
Low
Report
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises [Yahoo! Finance]
7/3
09:05 am
ntra
Natera (NTRA) Soared After a 43% Increase In Revenue [Yahoo! Finance]
Low
Report
Natera (NTRA) Soared After a 43% Increase In Revenue [Yahoo! Finance]
7/3
07:18 am
ntra
Natera's (NASDAQ:NTRA) investors will be pleased with their massive 314% return over the last five years [Yahoo! Finance]
Low
Report
Natera's (NASDAQ:NTRA) investors will be pleased with their massive 314% return over the last five years [Yahoo! Finance]
7/3
07:12 am
ntra
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy [Yahoo! Finance]
Medium
Report
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy [Yahoo! Finance]
7/3
07:00 am
ntra
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
Medium
Report
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
6/27
07:12 am
ntra
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer [Yahoo! Finance]
Low
Report
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer [Yahoo! Finance]
6/27
07:00 am
ntra
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
Low
Report
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
6/17
07:14 am
ntra
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients [Yahoo! Finance]
Low
Report
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients [Yahoo! Finance]
6/17
07:00 am
ntra
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
Low
Report
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
6/11
08:30 am
ntra
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? [Yahoo! Finance]
6/3
09:01 am
ntra
Natera, Inc. (NASDAQ: NTRA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $142.00 price target on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $142.00 price target on the stock.
6/3
08:00 am
ntra
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Low
Report
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
6/3
02:54 am
ntra
Natera (NTRA) Raised Initial 2024 Guidance in Q1 [Yahoo! Finance]
Low
Report
Natera (NTRA) Raised Initial 2024 Guidance in Q1 [Yahoo! Finance]
5/30
08:54 am
ntra
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024 [Yahoo! Finance]
Low
Report
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024 [Yahoo! Finance]
5/30
08:00 am
ntra
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
Low
Report
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
5/27
08:39 am
ntra
Liquid Biopsy Market is Expected to Reach $11.3 billion | MarketsandMarkets™ [Yahoo! Finance]
Low
Report
Liquid Biopsy Market is Expected to Reach $11.3 billion | MarketsandMarkets™ [Yahoo! Finance]
5/23
04:05 pm
ntra
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
Low
Report
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
5/23
07:41 am
ntra
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting [Yahoo! Finance]
Low
Report
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting [Yahoo! Finance]
5/23
07:30 am
ntra
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
Low
Report
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
5/17
03:21 am
ntra
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Natera, Inc. (NASDAQ: NTRA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
5/14
09:00 pm
ntra
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Low
Report
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
5/14
08:06 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Piper Sandler from $110.00 to $120.00. They now have an "overweight" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at Piper Sandler from $110.00 to $120.00. They now have an "overweight" rating on the stock.
5/13
11:22 am
ntra
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at BTIG Research from $100.00 to $125.00. They now have a "buy" rating on the stock.
Low
Report
Natera, Inc. (NASDAQ: NTRA) had its price target raised by analysts at BTIG Research from $100.00 to $125.00. They now have a "buy" rating on the stock.